Latest Intelligence on Therapy Area in South and Central America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Pfizer: shooting itself in the foot with Chantix study

New full data from a 52-week, Pfizer-sponsored study demonstrated no significant difference in six-month and one-year quit rates between a nicotine replacement therapy patch and Pfizer's Chantix. Although these results are disappointing for Pfizer, they open up the market to developmental vaccine treatments which are able to demonstrate greater safety and efficacy than available options.

Published By Datamonitor
30 Jul 2008
CommentWire
CommentWire

Pfizer: promising news for rheumatoid arthritis drug but pricing will be crucial

Promising Phase III rheumatoid arthritis data for Pfizer's oral tasocitinib are set to emerge at this year's American College of Rheumatology meeting. As a first-in-class drug with the potential to address the unmet need for oral small molecules to treat rheumatoid arthritis, Datamonitor believes that it will have a distinct advantage. However, reasonable pricing will be crucial to its success.

Published By Datamonitor
08 Nov 2010
Expert View
Expert View

Pfizer: expanding consumer health business through OTC Nexium deal

Recently, Pfizer and AstraZeneca announced that they have signed a deal giving Pfizer marketing rights for the OTC version of the gastroesophageal reflux disease drug Nexium. Along with the cash-generating potential, the deal also strengthens Pfizer's consumer healthcare division, which can act synergistically with the company's innovative pharma business, especially in the emerging markets.

Published By Datamonitor
22 Aug 2012
CommentWire
CommentWire

Pfizer: breakthrough for neuroendocrine tumor therapy

Pfizer has announced that a Phase III trial of Sutent in advanced pancreatic neuroendocrine tumors has reached its primary endpoint of improved progression-free survival. Given the niche, underserved nature of the advanced pancreatic neuroendocrine market, seeking a line extension in this indication may be a successful strategy for the company.

Published By Datamonitor
13 Mar 2009
Expert View
Expert View

Pfizer's novel NGF pain drug is potential game changer

Phase II clinical trials of tanezumab in osteoarthritis, chronic low back pain and interstitial cystitis have demonstrated the drug's analgesic efficacy across these three chronic pain settings. Despite safety concerns and a high price point, Datamonitor expects tanezumab to enjoy a significant first-in-class advantage in a potentially lucrative novel area of pain therapy.

Published By Datamonitor
08 Feb 2010
ResearchWire
ResearchWire

Pediatric vaccines: unmet needs create opportunities

Published By Datamonitor
21 Aug 2007
Expert View
Expert View

Pandemic threat reignites influenza vaccine market

The last few years have seen renewed interest in the vaccines market, overcoming the prevailing view that vaccines are a low-margin business with high barriers to entry. The flu vaccines market has been at the forefront of this trend, partially fuelled by fear of an impending pandemic. This trend is set to continue, although flu vaccine revenues will depend on ambitious coverage targets being met.

Published By Datamonitor
20 Apr 2006
Expert View
Expert View

Pandemic flu: gaps in preparedness remain

The current outbreak of influenza A (H1N1) is testing pandemic preparedness strategies across the globe. While widely implemented strategies seem to have prepared the world better than ever before, important gaps regarding the logistics of drug and vaccine distribution remain.

Published By Datamonitor
08 May 2009
ResearchWire
ResearchWire

Osteoporosis: market driven by pipeline products

Published By Datamonitor
06 Jul 2007
CommentWire
CommentWire

Osteologix and Servier: promising outlook for bone drug candidate

Servier and Osteologix have entered into an agreement for the development and commercialization of Osteologix's novel dual acting bone agent for the treatment of osteoporosis, NBS101. While this partnership bodes well for the outlook of the drug in Europe, a medium or large US partner would unlock the treatment's true commercial potential.

Published By Datamonitor
04 Aug 2010

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.